Blog Read the latest perspectives from our team of subject matter experts and others Ribbon Health and H1: Merging Missions to Transform HealthcareOn January 8th, we celebrated an exciting milestone: Ribbon Health merged with H1! This union represents a significant leap toward achieving our shared vision of transforming healthcare by ensuring… Continue reading → Read the article Post Topics:Artificial Intelligence Commercialization Drug Development Global Impact HCP Volunteers KOL Engagement Patient Representation Provider Data Research Post Industries:Commercialization Global Impact Health Plans & Digital Health Pharmaceutical & Biotechnology Provider Data Research Artificial IntelligenceCommercializationDrug DevelopmentPatient RepresentationH1’s Predictions for Healthcare and Pharma in 2025Each year, we compile our predictions to provide life sciences, pharmaceutical, and healthcare organizations with a comprehensive look at emerging industry trends and dynamics to help them prepare for the… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationFDA Poised to Make Impact on Underrepresented Populations in Clinical StudiesDiversity Action Plans (DAPs) aim to improve data that the FDA receives by increasing the clinical enrollment of historically underrepresented participants. Increasing diversity in clinical trials not only makes the… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationThe Opportunities and Challenges of Improving Health Equity with Expert Daniel PerezThe pursuit of health equity has many obstacles. Achieving a state where everyone has fair and equitable access to healthcare is a massive endeavor with many stakeholders. It requires addressing… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationEthics and Equity in Clinical Trials & FDA Diversity Guidance PrepClinical trials serve as the bedrock for advancements in medicine, guiding the development of new treatments and therapies. However, a critical issue plaguing these trials is the lack of… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchTrials, Data, Diversity – H1’s Top 5 Diagnoses (Predictions) for Biotech and Pharma in 2024How will AI impact clinical trials? Will FDA legislation improve diversity? What platforms will key opinion leaders adopt? Every year, we take a look at annual predictions to help life… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationWhy Clinical Trial Success Criteria Matters: 5 Essential QuestionsAs the pharmaceutical and biotech industries continue to push for faster drug development, the importance of equity and diversity in clinical trial recruitment cannot be overlooked. With the rise of… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationOptimizing Clinical Data Registries: Opportunities for Diversity and FeasibilityIn an October 2023 report, BMC Medicine completed a follow-up on a 10-year effort to understand, report on and track data sharing challenges with big pharma, specifically for clinical… Continue reading → Read the articleno Artificial IntelligenceCommercializationDrug DevelopmentPatient Representation7 Ways of Generating AI-produced ROI for Life SciencesFor life sciences companies, the application of AI has the potential to provide transformative value, not only in terms of direct financial return but also through operational, research, and clinical… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationThe Trust Fall: Building Successful & Diverse Trials Outside the U.S.As the U.S. ramps up for release of the latest COVID-19 vaccine booster, the Centers for Disease Control and Prevention (CDC) recommends that all Americans aged 6 months and… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationImproving Oncology Clinical Trials for Accelerated ApprovalIn March of 2023, the U.S. Food and Drug Administration (FDA) issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design specific… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationWhy Drug Approvals and Development Hinge on DiversityThe success of drug development and approval relies heavily on the ability to identify diverse patient populations for clinical trials. From trial site feasibility to successful trial recruitment, diversity within… Continue reading → Read the articleno Drug DevelopmentKOL EngagementPatient RepresentationBuilding an Exclusive Strategy with Inclusive HCPsAs healthcare providers (HCPs) are increasingly relying on evidence-based data and clinical guidelines, life science organizations must shift their focus to enabling HCPs in the effective adoption of these medicines.… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationFour Strategies for Preparing FDA Diversity Action PlansIn the race to bring new treatments and cures to market, clinical trial operations and feasibility teams often face a formidable challenge: ensuring that patient populations are accurately represented… Continue reading → Read the articleno Drug DevelopmentPatient Representation3 Ways CROs Can Expedite Clinical Trial Site SuccessClinical Research Organizations (CROs) play an important role in the success of clinical trials. They provide crucial resources, processes, and strategies to ensure that trials are conducted with the… Continue reading → Read the articleno KOL EngagementPatient RepresentationFour Ideas for Pharma to Maximize the Influence of Digital Opinion Leaders in MedicinePharmaceutical companies have long recognized the importance of engaging key opinion leaders (KOLs) to gain insight and support for clinical research, drug development, and medical education. With the rise… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationData Networks & Guiding Clinical Trials – Six Metrics for Powering Trials to Reach Vulnerable Patient PopulationsFor clinical operations and development clinical feasibility teams, diversity equity and inclusion and health equity leaders, as well as health economics and outcomes research (HEOR) teams, it is essential to… Continue reading → Read the articleno Drug DevelopmentPatient Representation3 Common Questions Related to Clinical Trial Performance DataOver the past decade, the cost and time impact to bring drugs to market have been increasing. With the recent trends in healthcare (more diversity and inclusion for both patients… Continue reading → Read the articleno CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Honored with a Spot on Y Combinator’s 2023 Best Companies List and Slice of Healthcare’s Inaugural Digital Health Leaders ListH1, the connecting force for global healthcare provider, clinical, science, and research information, today announced that it has been recognized in two prestigious annual lists: Y Combinator’s 2023 Best Companies… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationBest-Fit Sites for Clinical TrialsWhen evaluating the feasibility of a clinical trial, it’s essential to consider what success means. This can mean defining criteria for your patient population, principal investigator (PI) qualifications, and… Continue reading → Read the articleno Patient RepresentationHow to Build a Scalable Diversity StrategyPut simply – in 2022, clinical trial diversity, equity and inclusion (DEI) was top of mind for the pharma and biotech industries, across all phases of drug and device… Continue reading → Read the articleno Drug DevelopmentPatient RepresentationThree Essential Data Insights for Optimal Trial Site Feasibility, Inclusivity and SelectionWhen you google the term “clinical trial,” the first thing that comes up is the National Library of Medicine site all about clinical research. It’s a great foray and… Continue reading → Read the articleno CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchNew Look, Same Commitment!I’m excited to officially unveil the new branding and website our team has been working on for several months. This new branding comes with much thought and consideration, and reflects… Continue reading → Read the articleno CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchTimmy Awards Announces H1 as 2022 Tech for Good FinalistThe 8th Annual Timmy Awards run by Tech in Motion celebrates leaders in tech, recognizing the top workplaces for tech professionals across North America. We are thrilled to announce that H1 is… Continue reading → Read the article Drug DevelopmentPatient RepresentationThe ABCs (and Ds) of Clinical Trial DiversityWhen the FDA mandated guidelines earlier this year for broader clinical trial diversity and inclusion, it brought a long-standing challenge in pharma and life sciences into the spotlight. Here, Alexandra… Continue reading → Read the articleno Drug DevelopmentKOL EngagementPatient RepresentationA New Reflection on Pharma, Research, and Patient CarePharma has long existed in elevated, prestigious academic institutions: ivory towers of reputable and revered centers of excellence famous for disseminating the latest in clinical research and medical breakthroughs.… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchThe Evolution of H1’s Core ValuesI remember it clearly. Me, Ian – our co-founder and a handful of brave individuals who would become the first H1 employees, sitting around a table writing down the values… Continue reading → Read the article Drug DevelopmentPatient RepresentationEquitable Healthcare Starts with Medical AffairsBecause they serve as the bridge between research and commercial functions of life sciences companies, medical affairs can drive equity in clinical trials by proactively engaging with a diverse set… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Recognized as One of Forbes’ Best Startup Employers 2022H1, which provides the largest global healthcare professional data ecosystem to enable life sciences, academic medical institutions, health systems, and payers, today announced it has been included on Forbes’… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Named to NYC Digital Health 100 by NYCHBLH1, which provides the largest global healthcare platform that connects healthcare professionals, today announced that New York City Health Business Leaders (NYCHBL), the organization that serves as the gateway to… Continue reading → Read the article Drug DevelopmentPatient RepresentationMaking Clinical Trials More SuccessfulUtilizing all available data sources to optimize clinical trial design and planning, as well as adopting novel trial formats, such as decentralized trials, telehealth and mobile health applications, can get… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Wraps Up 2021 with Gratitude2021 was a year of enormous change around the world, as we learn to live and work in new ways. For H1, it was also a year of enormous growth,… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchCo-Founder and CEO of H1 Named to Forbes 30 Under 30H1 announced today that its CEO and Co-Founder Ariel Katz was named to the prestigious Forbes 30 under 30 list. Ariel started his first company in college, ResearchConnection, to help… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchZiad Ismail Joins H1 During Period of High GrowthH1, which provides the largest global healthcare network that connects healthcare professionals, announced today that it has added Ziad Ismail to the management team as Chief Operating Officer. Ziad… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Raises Series CToday we announced our Series C of $100 million led by Altimeter and participation from new investors including Goldman Sachs Asset Management and Flex Capital. It also includes the support… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchFormer Dropbox CIO Joins Board of Healthcare Data Startup H1Board member Sylvie Veilleux (Salesforce, Dropbox), CFO Karen Moran (Alteryx, Domo) and CDO Mayur Thakur (Goldman Sachs, Google) bring decades of experience and add bench strength as H1 expands.… Continue reading → Read the article Drug DevelopmentPatient RepresentationThe Post-Pandemic Future of Clinical TrialsIn a post-COVID world, we’re seeing a decade’s worth of reshaping within clinical trials solidify in less than a year. While the life sciences industry was making a slow… Continue reading → Read the article CommercializationDrug DevelopmentPatient RepresentationWhy Diversity Matters for PharmaDiversity matters for pharma because inclusion, trust and equity matter for pharma. When developing therapies and medications, pharmaceutical and life sciences companies are tasked with designing products for a… Continue reading → Read the article CommercializationDrug DevelopmentKOL EngagementPatient RepresentationProvider DataResearchH1 Closes $58 Million Series B FundingToday, H1 announced a $58 million Series B round of funding to continue working towards our mission of creating a healthier future by connecting parties in the healthcare ecosystem.… Continue reading → Read the article
